Search Results

You are looking at 1 - 10 of 512 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

NCCN Adjuvant Therapy for Breast Cancer Task Force Members *Robert W. Carlson, MD / Chair#†  ¶¶ Stanford Hospital and Clinics Donald A. Berry, PhD††  The University of Texas M. D. Anderson Cancer Center *Elizabeth Brown, MD  National Comprehensive

Full access

Does Use of the Adjuvant! Model Influence Use of Adjuvant Therapy Through Better Risk Communication?

Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff

P atients with breast cancer who are at relatively low risk for recurrence or mortality after local therapy (surgery with or without radiation) face a “grey zone” decision about whether to undergo adjuvant therapy. 1 The choice of therapy

Full access

Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain

Katherine Van Loon and Alan P. Venook

Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research

Full access

Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model

Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses

incorporated into practice guidelines for GA management in the United States. Subsequently, several retrospective population-based studies have reaffirmed the benefit of adjuvant therapy in patients undergoing curative-intent gastrectomy. 7 – 9 Based on these

Full access

Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

Although perioperative chemotherapy and postoperative chemoradiation are the 2 evidence-based options for gastric cancer, 4 , 6 ongoing multicenter trials are investigating whether strategies that move most or all of the adjuvant therapy to the

Full access

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Michael S. Sabel and Vernon K. Sondak

: 3635 – 3648 . 2 Dickler MN Coit DG Myers ML . Adjuvant therapy of malignant melanoma . Surg Oncol Clin N Am 1997 ; 6 : 793 – 812 . 3 Pfeffer LM Dinarello CA Herberman RB . Biological properties of recombinant alpha

Full access

Patient Navigation for Timely, Guideline-Adherent Adjuvant Therapy for Head and Neck Cancer: A National Landscape Analysis

Evan M. Graboyes, Michelle Chappell, Kelsey A. Duckett, Katherine Sterba, Chanita Hughes Halbert, Elizabeth G. Hill, Bhishamjit Chera, Jessica McCay, Sidharth V. Puram, Salma Ramadan, Vlad C. Sandulache, Russel Kahmke, Brian Nussenbaum, Anthony J. Alberg, Electra D. Paskett, and Elizabeth Calhoun

-adherent adjuvant therapy and worse oncologic outcomes for patients with HNC. 2 – 7 In addition, the metric was selected because there is a quality-of-care gap, with approximately 50% of patients failing to commence PORT within the recommended 6-week interval. 2

Full access

CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma

John Khoury, David Macari, Daniel Ezekwudo, Ayoda Werede, and Ishmael A. Jaiyesimi

Background: There is controversy surrounding the benefit of adjuvant therapy for patients with pT2N0, stage IB gastric adenocarcinoma following surgical resection. Methods: Patients with T2N0 gastric adenocarcinoma (tumor invasion into the

Full access

Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

Leslie A. Fecher and Keith T. Flaherty

alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 . J Clin Oncol 1996 ; 14 : 7 – 17 . 11 Kirkwood J Manola J Ibrahim J . A pooled analysis of eastern cooperative

Full access

Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy

Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer

Questionnaire (IIQ-7) 15 before and 3 months after initiation of (neo)adjuvant therapy. Patients with metastatic cancer or currently or previously undergoing treatment by a urologist were excluded from participation. Participants were approached by the treating